eTheRNA was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy.
Later on eTheRNA entered into a partnership with Progress Pharma under the leadership of Dirk Reyn, former CEO of Movetis, who now heads eTheRNA immunotherapies management team. In July of that year, eTheRNA obtained from the VUB a worldwide exclusive license on the TriMix technology.
eTheRNA immunotherapies’ mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system.
eTheRNA immunotherapies NV
2845 Niel – Belgium
Phone: +32 3 369 17 40